Absci Corporation (ABSI)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Absci details clinical strategy and AI platform for novel therapeutics
# 📰 What This Document Is 📖 This document is an Annual Report on Form 10-K, which is one of the most comprehensive reports a public company files with the SEC. Think of it as a massive, deep dive into the company's entire year—its finances, its risks, its management's plans, and its history. Bec
Absci advances AI biologics, targeting A.A. and Endometriosis milestones
# 🗳️ What This Document Is This document is a Definitive Proxy Statement (DEF 14A) for Absci Corp’s 2026 Annual Meeting of Stockholders. Simply put, this is a massive, formal letter from the company to its shareholders that details not only the important operational updates (like new drug progress)
SEC filings
All filings →Insider trades
All insider trades →Absci Corporation has no reported insider trades in the last 90 days.